| Year |
Citation |
Score |
| 2019 |
Ignacio DN, Mason KD, Hackett-Morton EC, Albanese C, Ringer L, Wagner WD, Wang PC, Carducci MA, Kachhap SK, Paller CJ, Mendonca J, Li-Ying Chan L, Lin B, Hartle DK, Green JE, et al. Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40. Heliyon. 5: e01128. PMID 30705983 DOI: 10.1016/J.Heliyon.2019.E01128 |
0.599 |
|
| 2014 |
Ringer L, Sirajuddin P, Tricoli L, Waye S, Choudhry MU, Parasido E, Sivakumar A, Heckler M, Naeem A, Abdelgawad I, Liu X, Feldman AS, Lee RJ, Wu CL, Yenugonda V, et al. The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget. 5: 10678-91. PMID 25296977 DOI: 10.18632/Oncotarget.2528 |
0.738 |
|
| 2014 |
Pollock CB, McDonough S, Wang VS, Lee H, Ringer L, Li X, Prandi C, Lee RJ, Feldman AS, Koltai H, Kapulnik Y, Rodriguez OC, Schlegel R, Albanese C, Yarden RI. Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells. Oncotarget. 5: 1683-98. PMID 24742967 DOI: 10.18632/Oncotarget.1849 |
0.719 |
|
| 2012 |
Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Üren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E, et al. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. Cell Cycle (Georgetown, Tex.). 11: 3801-9. PMID 22983062 DOI: 10.4161/Cc.21988 |
0.712 |
|
| 2012 |
Sirajuddin P, Das S, Ringer L, Salinas P, Rodriguez O, Moasser B, Yenugonda VM, Albanese C, Brown M. Abstract 4774: LC-MS/MS detection of the dansyl-modified biologically active CDK inhibitor VMY-1-103 using an in vivo model system Cancer Research. 72: 4774-4774. DOI: 10.1158/1538-7445.Am2012-4774 |
0.72 |
|
| 2012 |
Ringer L, Sirajuddin P, Yenugonda VM, Brown M, Rodriguez O, Albanese C. Abstract 3052: Role of p53 in cdk inhibitor VMY-1-103-induced apoptosis in prostate cancer Cancer Research. 72: 3052-3052. DOI: 10.1158/1538-7445.Am2012-3052 |
0.758 |
|
| 2011 |
Ringer L, Sirajuddin P, Heckler M, Ghosh A, Suprynowicz F, Yenugonda VM, Brown ML, Toretsky JA, Uren A, Lee Y, MacDonald TJ, Rodriguez O, Glazer RI, Schlegel R, Albanese C. VMY-1-103 is a novel CDK inhibitor that disrupts chromosome organization and delays metaphase progression in medulloblastoma cells. Cancer Biology & Therapy. 12: 818-26. PMID 21885916 DOI: 10.4161/Cbt.12.9.17682 |
0.748 |
|
| 2011 |
Beauchamp EM, Ringer L, Bulut G, Sajwan KP, Hall MD, Lee YC, Peaceman D, Ozdemirli M, Rodriguez O, Macdonald TJ, Albanese C, Toretsky JA, Uren A. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. The Journal of Clinical Investigation. 121: 148-60. PMID 21183792 DOI: 10.1172/Jci42874 |
0.61 |
|
| 2010 |
Ringer L, Sirajuddin P, Yenugonda VM, Ghosh A, Divito K, Trabosh V, Patel Y, Brophy A, Grindrod S, Lisanti MP, Rosenthal D, Brown ML, Avantaggiati ML, Rodriguez O, Albanese C. VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biology & Therapy. 10: 320-5. PMID 20574155 DOI: 10.4161/Cbt.10.4.12208 |
0.759 |
|
| 2010 |
Vissapragada S, Ghosh A, Ringer L, Salinas P, Brophy A, Peaceman D, Kallakury B, Banerjee PP, Fricke ST, Helfrich W, Lee YC, Pestell R, Scherer P, Tanowitz HB, Avantaggiati ML, et al. Dietary n-3 polyunsaturated fatty acids fail to reduce prostate tumorigenesis in the PB-ErbB-2 x Pten(+/-) preclinical mouse model. Cell Cycle (Georgetown, Tex.). 9: 1824-9. PMID 20404514 DOI: 10.4161/Cc.9.9.11542 |
0.612 |
|
| Show low-probability matches. |